approaching the treatment of patients with lbcl who relapse after bispecific antibodies
Published 2 months ago • 120 plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
1:05
where do bispecific antibodies fit into the large cell lymphoma treatment landscape?
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
3:43
key considerations when deploying bispecific antibodies for the treatment of b-cell malignancies
-
52:19
"cues guiding and restraining b cell responses" by dr. jason cyster
-
28:55
blending biophysics and machine learning to predict the antibody response -tal einav, ph.d.
-
35:48
control sections for ihc and if applications
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
0:55
the safety and efficacy of elranatamab in patients with r/r al amyloidosis
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:02
bispecific agents: the future of aml and mds treatment?
-
2:04
the importance of individualizing treatment approaches in hl to improve patient outcomes
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:42
optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma
-
2:47
a study comparing br to ibrutinib in the frontline treatment of waldenström's macroglobulinemia
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
5:15
the promise of immunotherapies in t-cell lymphoma
-
16:01
a. ahmed | patient blood management guidelines; the role of miecc
-
1:09
outpatient dosing of bispecific antibodies: what do clinicians need to consider?